Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-887-6 | CAS number: 75-63-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- other: Case report
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: The person involved in the accident had been a smoker for about 10 years; there was no analytical verification of the fumes the person inhaled.
Data source
Reference
- Reference Type:
- publication
- Title:
- Reactive airways dysfunction syndrome following exposure to a fluorocarbon
- Author:
- R.E. de la Hoz
- Year:
- 1 999
- Bibliographic source:
- Eur Respir J 1999; 13: 1192-1194
Materials and methods
- Study type:
- poisoning incident
Test material
- Reference substance name:
- Bromotrifluoromethane
- EC Number:
- 200-887-6
- EC Name:
- Bromotrifluoromethane
- Cas Number:
- 75-63-8
- Molecular formula:
- CBrF3
- IUPAC Name:
- bromotrifluoromethane
- Test material form:
- gas
Constituent 1
- Specific details on test material used for the study:
- greyish fumes, leaking out of the CF3Br-based fire extinguishing system
Method
- Type of population:
- occupational
- Subjects:
- - Number of subjects exposed: 1
- Sex: male
- Age: 36 years; symptoms started when he was 43 years old.
- Race: caucasian
- Known diseases: according to the publication, the person was "previously healthy". He had no history of any lung disease before the incident and had no significant history of exposure to dusts or fumes. He did not have any known allergies. The person had been a smoker (about half a pack of cigarettes daily) for 10 years until 3 years before the exposure to CF3Br. - Reason of exposure:
- accidental
- Exposure assessment:
- estimated
- Details on exposure:
- A technician, responsible for the repair of computerized material was located in a large room in the basement of a hospital when one tank of the CF3Br-based automatic fire extinguishing system suddenly leaked greyish fumes from the ceiling directly above the technician. Exposure duration was estimated to have been ~10-15 minutes to a concentration of at least 15%.
- Medical treatment:
- In the hospital he recieved no medication. 3±4 days later, his physician prescribed an inhaled bronchodilator, terfenadine,and a vasoconstrictor.
Two weeks after the episode, he was treated with oral prednisone (50 mg.day-1 for 1 week), then salbutamol and triamcinolone by metered-dose inhalers (MDI).
Results and discussion
- Results of examinations:
- The person immediately experienced eye irritation and shortness of breath. After having left the room, he noticed increasing chest tightness, dizziness and lightheadedness. He was immeadiately taken to the hospital, where the mediccal staff documented the precence of conjunctivitis, tachypnoea and wheezing. Approx. 4 hours later he was released to his home without medication.
During the next few days he experienced severe tiredness, persistent eye irritation, chest tightness and some cough. Within a few more days, the
patient was evaluated by another physician, who found a decreased forced expiratory volume in one second (FEV1) (50% of predicted) and forced vital
capacity (FVC) (70% pred).
Five weeks after the episode an examining pulmonologist reported the presence of conjunctivitis, but no wheezing. Spirometry showed obstructive impairment, with a clear response to an inhaled bronchodilator (FEV1 increased by 13% from 3.79 L). - Effectivity of medical treatment:
- Two weeks after the episode, when he was treated with oral prednisone, then salbutamol and triamcinolone by MDI, the patient experienced partial improvement
of his symptoms of cough, shortness of breath at rest or on exertion, eye irritation, and fatigue.
Five weeks after the episode an examining pulmonologist reported the presence of conjunctivitis, but no wheezing. Spirometry showed obstructive impairment, with a clear response to an inhaled bronchodilator (FEV1 increased by 13% from 3.79 L). - Outcome of incidence:
- Three years after the episode the patient continued to experience episodes of shortness of breath and mostly nonproductive cough. He also has perennial noninfectious rhinoconjuctivitis. His symptoms seemed to worsen with cold weather and high environmental humidity, strong smells (e.g. from paints), heavy traffic smog, and dust. The respiratory symptoms have no seasonal pattern, and respond to inhaled medications.
Applicant's summary and conclusion
- Conclusions:
- The authors concluded that the inhalation of CF3Br or a decomposition product of CF3Br might be responsible for the development of athe reactive airways dysfunction syndrome of the person.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.